AlloVir, Inc. has entered into a merger agreement with Kalaris Therapeutics, where Kalaris will become a wholly owned subsidiary of AlloVir, with Kalaris shareholders owning approximately 74.95% and AlloVir shareholders owning about 25.05% of the combined company post-merger, based on a valuation of $116 million for AlloVir and $347 million for Kalaris.